Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebastinib Plus Paclitaxel or Eribulin in Metastatic Breast Cancer
NCT02824575Phase 1Terminated
- Sponsor
- Montefiore Medical Center
- Start
- Jul 2016
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rebastinib in breast cancer (2 arms), sponsored by Montefiore Medical Center. Primary endpoint: Recommended Phase 2 Dose at 3 weeks. Started Jul 2016; status: terminated.
02
Drugs
rebastinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02824575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824575.